...
首页> 外文期刊>International Journal of Biological Macromolecules: Structure, Function and Interactions >Ultrasensitive bioassay of epitope of Mucin-16 protein (CA 125) in human plasma samples using a novel immunoassay based on silver conductive nano-ink: A new platform in early stage diagnosis of ovarian cancer and efficient management
【24h】

Ultrasensitive bioassay of epitope of Mucin-16 protein (CA 125) in human plasma samples using a novel immunoassay based on silver conductive nano-ink: A new platform in early stage diagnosis of ovarian cancer and efficient management

机译:基于银导纳米油墨的新型免疫测定的人血浆样品中粘液-16蛋白(CA 125)表位的超敏感性生物测定:卵巢癌及高效管理早期诊断的新平台

获取原文
获取原文并翻译 | 示例
           

摘要

Ovarian cancer (OC) is known to be one of the most lethal malignancies associated with women disease. The CA-125 protein is a repetitive epitope of MUC-16, which plays key role in enhancing the proliferation of cancer cells and inhibiting anticancer immune responses. It is the most widely used biomarker for early stage diagnosis of OC. Also it is the only serum marker which currently used in clinical diagnosis. Monitoring of CA-125 protein in the serum sample is also valuable in evaluating the response of ovarian cancer to treatment. In this research, a novel immunoassay based on immobilization of CA-125 antibody on the biointerface of silver nanoparticles modified graphene quantum dots ink (Ag NPs-GQDs) was successfully designed to recognition of CA-125 protein in a human plasma sample. The supplied immunoassay presents the proper ability to detect and determine the amount of CA-125 biomarker in low concentrations of CA-125 biomarker. The proposed immunosensor was employed for the detection of CA-125 using differential pulse voltammetry (DPVs) and square wave voltammetry (SWV5) techniques. The proposed interface leads to enhancement of accessible surface area for immobilizing a high amount of anti-CA-125 antibody, increasing electrical conductivity, boosting stability, catalytic properties and biocompatibility. Under the optimized operating conditions, the low limit of quantitation (LLOQ) for the proposed immunosensor was recorded as 0.01 U/mL, which this evaluation was performed at highly linear range of 0.01-400 U/mL The proposed immunoassay was successfully applied for the monitoring of CA-125 in unprocessed human plasma samples. (C) 2019 Published by Elsevier B.V.
机译:众所周知,卵巢癌(OC)是与女性疾病相关的最致命恶性肿瘤之一。 Ca-125蛋白是MUC-16的重复表位,其在提高癌细胞增殖和抑制抗癌免疫应答方面发挥着关键作用。它是使用最广泛使用的生物标志物,用于OC的早期诊断。此外,它是目前用于临床诊断的唯一血清标记。在血清样品中监测Ca-125蛋白也有价值在评估卵巢癌治疗的响应方面是有价值的。在该研究中,成功​​地设计了基于银纳米甲烯量子点油墨(Ag NPS-GQDS)的生物缠结的Ca-125抗体的新型免疫测定,以识别人血浆样品中的Ca-125蛋白。所提供的免疫测定呈现出正确检测和确定低浓度Ca-125生物标志物的Ca-125生物标志物的能力。所提出的免疫传感器用于CA-125的使用微分脉冲伏安法(DPVS)和方波伏安法(SWV5)技术进行检测。所提出的界面导致增强可接近的表面积,用于固定大量的抗CA-125抗体,增加电导率,提高稳定性,催化性质和生物相容性。在优化的操作条件下,所提出的免疫传感器的定量低限制(LLOQ)被记录为0.01u / ml,该评估在0.01-400 U / mL的高度线性范围内进行,所以已提出的免疫测定成功施加监测未加工的人血浆样品中的CA-125。 (c)2019年由elestvier b.v发布。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号